

# Riaz Qureshi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5587961/publications.pdf>

Version: 2024-02-01

18  
papers

185  
citations

1162367

8  
h-index

1125271

13  
g-index

23  
all docs

23  
docs citations

23  
times ranked

111  
citing authors

#	ARTICLE	IF	CITATIONS
1	Harms in Systematic Reviews Paper 1: An introduction to research on harms. <i>Journal of Clinical Epidemiology</i> , 2022, 143, 186-196.	2.4	30
2	Evaluation of Systematic Reviews of Interventions for Retina and Vitreous Conditions. <i>JAMA Ophthalmology</i> , 2019, 137, 1399.	1.4	21
3	Gender and Editorial Authorship in High-Impact Epidemiology Journals. <i>American Journal of Epidemiology</i> , 2019, 188, 2140-2145.	1.6	21
4	Harms in Systematic Reviews Paper 2: Methods used to assess harms are neglected in systematic reviews of gabapentin. <i>Journal of Clinical Epidemiology</i> , 2022, 143, 212-223.	2.4	17
5	Harms in Systematic Reviews Paper 3: Given the same data sources, systematic reviews of gabapentin have different results for harms. <i>Journal of Clinical Epidemiology</i> , 2022, 143, 224-241.	2.4	16
6	Accuracy of optical coherence tomography for diagnosing glaucoma: an overview of systematic reviews. <i>British Journal of Ophthalmology</i> , 2021, 105, 490-495.	2.1	13
7	What Do We Really Know about the Effectiveness of Glaucoma Interventions?. <i>Ophthalmology Glaucoma</i> , 2021, 4, 454-462.	0.9	13
8	Effect of redundant clinical trials from mainland China evaluating statins in patients with coronary artery disease: cross sectional study. <i>BMJ, The</i> , 2021, 372, n48.	3.0	11
9	The Relationship of APOE $\epsilon$ 4, Race, and Sex on the Age of Onset and Risk of Dementia. <i>Frontiers in Neurology</i> , 2021, 12, 735036.	1.1	11
10	The SPIRIT Checklist—lessons from the experience of SPIRIT protocol editors. <i>Trials</i> , 2022, 23, 359.	0.7	8
11	Authorship diversity among systematic reviews in eyes and vision. <i>Systematic Reviews</i> , 2020, 9, 192.	2.5	5
12	Association between switching of primary outcomes and reported trial findings among randomized drug trials from China. <i>Journal of Clinical Epidemiology</i> , 2021, 132, 10-17.	2.4	4
13	Assessment of Duplicate Publication of Chinese-Sponsored Randomized Clinical Trials. <i>JAMA Network Open</i> , 2020, 3, e2027104.	2.8	4
14	Visualising harms in publications of randomised controlled trials: consensus and recommendations. <i>BMJ, The</i> , 2022, 377, e068983.	3.0	4
15	How Can We Quantify and Compare Harm in Surgical Trials?. <i>American Journal of Ophthalmology</i> , 2022, 241, 64-70.	1.7	2
16	Registration of phase 3 crossover trials on ClinicalTrials.gov. <i>Trials</i> , 2020, 21, 613.	0.7	1
17	The Importance of Reporting Biases in Patient Care: Can We Trust the Evidence From Either Individual Studies or Systematic Reviews?. <i>Annals of Internal Medicine</i> , 2018, 169, 413.	2.0	0
18	Reply. <i>Ophthalmology</i> , 2019, 126, e28-e29.	2.5	0